MedTrace Logo

Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma

NCT05738161 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2024-07-05

No results posted yet for this study

Summary

In their "Magrolimab" research project, the investigators want to find out whether the new drug Magrolimab in combination with conventional chemotherapy is well tolerated and whether survival or progression-free survival improves.

Conditions

  • Advanced Urothelial Carcinoma

Interventions

DRUG

Magrolimab

Magrolimab in combination with cytotoxic chemotherapy in advanced urothelial carcinoma

DRUG

Cisplatin

Standard first line platinum-based chemotherapy in advanced urothelial carcinoma

DRUG

Gemcitabine

Standard first line platinum-based chemotherapy in advanced urothelial carcinoma

Sponsors & Collaborators

  • University of Bern

    collaborator OTHER

  • Swiss National Science Foundation

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Bernhard Kiss, Professor · Universtary Hospital Insel Bern

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-21
Primary Completion
2024-02-27
Completion
2024-02-27

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05738161 on ClinicalTrials.gov